KA
Therapeutic Areas
Arrivo BioVentures Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SP-624 (Forvisirvat) | Major Depressive Disorder | Phase 2 |
| RABI-767 | Predicted Severe Acute Pancreatitis | Phase 2 |
Leadership Team at Arrivo BioVentures
SE
Stephen E. Butts
Chief Executive Officer
JH
John Hixon
Head of Corporate Development
JR
Joel Raskin
Chief Medical Officer
GR
Greg Rigdon
Senior Vice President, Scientific Affairs
KA
Kelly Abernathy
Chief Operating Officer
BL
Bruce Leuchter, MD
Board Member